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MuTAR study, Phase II,
open-label study of erlotinib (E)
Table  1  Best  overall  response:  RECIST  criteria  --  ITT
population.Total  (n  =  30)
Best  overall  response,  n  (%)
Complete  response  0  0.00%
Partial  response  19  63.33%
Stable  disease  9  30.00%
Progressive  disease  1  3.33%
Inevaluable  0  0.00%
Not available/not
accessed
1  3.33%
Total 30a 100.0%
Objetive  response
rateb,  n  (%),  95%  CI
19  (63.33%),  [0.4609,  0.8058]
a For the 7 patients without information of overall response at
the end of the study visit, best overall response was  obtained
according to the information from the study treatment visits
available.
b Objective response rate: patients with complete or partial
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Atreatment in patients (pts) with
locally advanced or metastatic
non-small cell lung cancer
(mNSCLC) who present
activating mutations (MUT+) in
the  tyrosine kinase (TKI)
domain of the epidermal
growth factor receptor (EGFR),
assessed the efﬁcacy of 1L in
Portuguese pts with mNSCLC
EGFR Mut+
Clinical notes
Activating  mutations  in  EGFR  are  important  markers  of
response  to  TKI  therapy  in  mNSCLC.1,2 In  robust  phase  3
trials,  erlotinib  (E)  has  been  shown  to  improve  progression
free  survival  (PFS),  compared  with  chemotherapy  (CT),  in
ﬁrst-line  treatment  (1L),  patients  with  mNSCLC  EGFR  MUT+,
ORR  --  58%,  PFS  --  9.7  months  and  overall  survival  (OS)  22.9
months  in  caucasions.1,2 MuTAR  study,  assessed  the  efﬁcacy
of  1L  Erlotinib  in  portuguese  pts.
We  undertook  this  open-label  multicenter,  phase  II  trial,
at  9  hospitals  in  Portugal.  Eligible  patients  included  adult
patients  with  histologically  or  cytological  documented  inop-
erable  mNSCLC  EGFR  MUT+  with  no  history  of  chemotherapy
or  therapy  against  metastatic  disease.
Treatment  consisted  of  Erlotinib  150  mg/day  per  os,  in
tablet  form,  until  disease  progression,  unacceptable  toxic-
ity,  death  or  withdrawal  of  consent.
The  primary  efﬁcacy  endpoint  was  objective  response
rate  (ORR),  deﬁned  as  complete  or  partial  response  accord-
ing  to  RECIST  version  1.1.
An  interim  analysis  was  conducted  with  a  cut-off  date
on  the  30th  September  2013,  to  analyse  preliminary  clinical
beneﬁts  and  compare  it  with  the  available  literature.  At  the
time  of  interim  analysis,  3  patients  were  still  in  treatment.
The  recruitment  period  was  between  February  2011  and
March  2012.  Of  the  216  screened  patients,  205  performed
EGFR  mutation  test,  with  38  showing  activating  EGFR
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95% CI: 95% conﬁdence interval.
utations  and  30  (14.6%)  were  eligible  to  be  included  in
he  study  (44.7%  with  exon  19  and  55.3%  with  exon  21).
he  ORR  (ITT  population)  was  63.3%  (95%CI:  46.1%--80.6%)
Table  1).  The  median  PFS  and  overall  survival  (OS)  (ITT
opulation)  were  10  months  (95%CI:  7.7--16)  and  20.7
onths  respectively.  A  total  of  340  adverse  events  (AE)
ere  observed  in  29  patients;
In  conclusion,  E  in  1L  treatment  of  mNSCLC  EGFR
ut  +  pts  showed  similar  results  compared  with  other  clinical
rials  in  Caucasian  patients  regarding  ORR,  PFS  and  OS.  First-
ine  E  was  effective  and  well  tolerated  in  Portuguese  EGFR
ut  +  patients.  Our  ﬁndings  strengthen  also  the  rationale  for
outine  baseline  assessment  of  EGFR  mutation  status  in  pts
ith  mNSCLC  and  for  treatment  beneﬁt  of  mutation  positive
atients  with  EGFR  TKIs.
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ransbronchial cryobiopsy in
he  diagnosis of desquamative
nterstitial pneumonia
esquamative  interstitial  pneumonia  (DIP)  is  a  rare  intersti-
ial  pneumonia  usually  associated  with  cigarette  smoke.1,2
t  is  characterized  by  the  accumulation  of  intra-alveolar
acrophages,  sometimes  associated  with  giant  cells.1,3 The
iagnosis  may  be  suggested  by  patchy  ground-glass  opaci-
cation  with  a  predilection  for  the  mid  and  lower  lung
obes  on  high-resolution  computed  tomography  (HRCT);
ubpleural  involvement  is  also  typical.  Irregular  lines,  trac-
ion  bronchiectasis,  cysts,  emphysema,  and  nodules  are
ther  possible  ﬁndings  of  DIP.4 Bronchoalveolar  lavage  ﬂuid
early  always  contains  an  increased  number  of  alveolar
acrophages.2,4 Histologically,  DIP  is  characterized  by  the
ccumulation  of  macrophages  in  the  alveolar  spaces  asso-
iated  with  interstitial  inﬂammation  and/or  ﬁbrosis.  The
acrophages  usually  contain  light  brown  pigment.  Lymphoid
odules  and  a  sparse  but  distinct  eosinophilic  inﬁltrate  are
ommon.3 Surgical  lung  biopsy  is  still  required  to  make  a
eﬁnitive  diagnosis.1--3
Transbronchial  lung  cryobiopsy  (TBLC)  is  a  new  endo-
copic  technique  that  has  recently  shown  superior  diagnostic
ield  to  conventional  transbronchial  biopsy  (TBB).5--7 The
dvantage  of  the  cryoprobe,  compared  with  conventional
BB  or  TBB  using  jumbo  forceps  is  that  larger  pieces  of  tis-
peripheral  structures  of  the  secondary  pulmonary  lobule  and
facilitates  immunohistochemical  staining.  In  addition,  TBLC
can  be  performed  on  an  outpatient  basis  and  is  both  an  eas-
ier  and  safer  procedure  for  patients  with  comorbidities,  as
it  reduces  the  complications  and  mortality  associated  with
surgical  lung  biopsy.6
Most  of  the  data  available  to  date  is  on  TBLC  overall
diagnostic  yield  and  complication  rates.5 However,  it  is  also
important  for  clinicians  to  know  the  diagnostic  accuracy  of
TBLC  in  particular  diffuse  lung  diseases,  especially  in  cases
in  which  histologic  evaluation  is  an  essential  component  of
multidisciplinary  diagnostic  approach,  as  is  the  case  with
DIP.
Our  aim  was  to  investigate  the  diagnostic  accuracy  of
TBLC  in  patients  with  clinical  and  radiological  ﬁndingsue,  without  crush  artifacts,  can  be  extracted  during  the
reeze-thaw  cycle,  allowing  the  identiﬁcation  of  complex
athologic  patterns.  The  technique  permits  visualization  of
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igure  1  HRCT  scan  showing  ground-glass  pattern  in  the  lower
ulmonary  lobes.
